Bremen, February 14, 2012 - MeVis Medical Solutions AG [ISIN: DE000A0LBFE4], a leading software provider for the medical imaging market, has achieved based on preliminary figures, a Group turnover for fiscal year 2011 of approx. EUR 13.7 million (previous year: EUR 14.3 million) and an EBITDA of around EUR 4.1 million (previous year: EUR 3.5 million). The Group EBIT of approx. EUR -1.7 million (previous year: EUR -5.4 million) was burdened by mainly non-cash, one-time charges. Compared to the previous year, Group EBIT before one-time charges was improved by approx. EUR 0.2 million to approx. EUR 0.9 million.
The one-time charges impacting the EBIT consist of a non-cash impairment charge on intangible assets in the amount of approx. EUR 2.3 million for capitalized development expenses of Visia Software Applications since 2008. In addition, a provision has been made for the contractual obligations to the CEO, Dr. Carl Evertsz, who will leave the company on February 29, 2012.
The financial result was impacted by a partial write-off of the 41% stake in the Dutch company Medis in the amount of EUR 0.9 million. This non-cash write-off was due to an adjusted assessment of the future development.
On December 31, 2011 the Group’s liquidity amounted to EUR 7.6 million. Liquidity therefore decreased by just EUR 0.6 million, despite a EUR 3.0 million payment in 2011 for the acquisition of the 49% stake in the MBS KG in 2008.
The complete consolidated financial statement, the Group management report and the forecast for the current fiscal year will be released on April 24, 2012.